Description
Provider of personalized medical treatments designed to focus on the treatment of cancer. The company's offers treatments through a technology platform that can generate autologous and allogeneic cellular immune therapies to target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs for clinical applications, thereby enabling patients to get rid of chronic viral diseases quickly and painlessly.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Merger/Acquisition | 30-May-2018 | 000.00 | Completed | Startup | ||
3. Accelerator/Incubator | 000.00 | Completed | Startup | |||
2. Accelerator/Incubator | 14-Sep-2013 | $57.9K | Completed | Startup | ||
1. Seed Round | 01-May-2013 | $57.9K | $57.9K | Completed | Startup |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2016274633-A1 | Methods for the production of tcr gamma delta+ t cells | Pending | 09-Jun-2015 | 000000000 | |
EP-3307875-A1 | Methods for the production of tcr gamma delta+ t cells | Pending | 09-Jun-2015 | 0000000000 | |
US-20180169147-A1 | Methods for the production of tcr gamma delta + t cells | Granted | 09-Jun-2015 | 000000000 | 0 |
JP-6799895-B2 | Production method of tcrγδ + t cells | Active | 09-Jun-2015 | 000000000 | |
US-20210361708-A1 | Methods for the production of tcr gamma delta + t cells | Pending | 09-Jun-2015 | C12N5/0638 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Biocant Park | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
Bynd Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Lisbon Challenge | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
PME Investimentos | Investment Bank | Minority | 000 0000 | 000000 0 | |
Portugal Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |